Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Arrowhead Pharmaceuticals Inc. (ARWR) Posts FY21 Loss of $1.36/Share
November 22, 2021 4:03 PM ESTArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported FY 2021 EPS of ($1.36), versus ($0.84) last year.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
... More